高托品酮肟 | 6164-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 高托品酮肟
• 中文别名: 9-甲基-9-氮杂双环[3,3,1]壬烷-3-肟；9-甲基-9-氮杂双环[3.3.1]壬烷-3-酮肟；ENDO-9-甲基-9-氮杂双环〔3,3,1〕壬-3-胺
• 英文名称: 9-methyl-9-aza-bicyclo[3.3.1 ]nonan-3-one oxime
• 英文别名: 9-Methyl-9-aza-bicyclo[3.3.1]nonan-3-on-oxim；9-Methyl-9-azabicyclo[3.3.1]nonan-3-one oxime；N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-ylidene)hydroxylamine
• CAS: 6164-67-6
• 化学式: C₉H₁₆N₂O
• 分子量: 168.239
• InChiKey: PUMZOLVVVUXXHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  126-127 ºC
• 沸点：
  281 ºC
• 密度：
  1.27
• 闪点：
  124 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 包装等级：
  II
• 危险类别：
  4.1
• 危险性防范说明：
  P201,P202,P280,P210,P240,P264,P270,P301+P310,P330,P370+P378,P403+P233,P405,P501
• 危险品运输编号：
  1325
• 危险性描述：
  H228,H312,H317,H318,H351

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Pseudopelletierine oxime
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Pseudopelletierine oxime
CAS number: 6164-67-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H16N2O
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  高托品酮肟 在 盐酸 、 ammonium acetate 、 氢气 、 碳酸氢钠 作用下， 以 甲醇 、 乙醇 、 甲基叔丁基醚 、 水 为溶剂， 反应 32.0h， 生成 exo-3-Amino-9-methyl-9-azabicyclo[3,3,1]nonane
  参考文献：
  名称：

  一种格拉司琼中间体的制备方法

  摘要：

  本发明公开了一种格拉司琼中间体的制备方法，包括如下步骤：步骤1：由式Ⅲ的丙酮二羧酸经过曼尼希反应得到式Ⅳ的假石榴皮碱；步骤2：由假石榴皮碱与羟胺反应制备式Ⅴ的3‑高托品酮肟；步骤3：采用以下方案之一：一：3‑高托品酮肟经红铝和路易斯酸催化还原得到式Ⅰ的3α‑高托品烷胺粗品，3α‑高托品烷胺粗品直接用于格拉司琼的制备或3α‑高托品烷胺粗品经纯化后用于格拉司琼的制备；二：3‑高托品酮肟经兰尼镍催化加氢还原得到高托品烷胺的混合物，纯化后得到式Ⅰ的3α‑高托品烷胺，再用于格拉司琼的制备。本发明反应条件比较温和，反应收率较高，成本较低，适合工业化生产。

  公开号：

  CN110804051B
• 作为产物：
  描述：

  9-甲基-9-氮杂双环[3.3.1]壬-3-酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以0.14 kg的产率得到高托品酮肟
  参考文献：
  名称：

  一种格拉司琼中间体的制备方法

  摘要：

  本发明公开了一种格拉司琼中间体的制备方法，包括如下步骤：步骤1：由式Ⅲ的丙酮二羧酸经过曼尼希反应得到式Ⅳ的假石榴皮碱；步骤2：由假石榴皮碱与羟胺反应制备式Ⅴ的3‑高托品酮肟；步骤3：采用以下方案之一：一：3‑高托品酮肟经红铝和路易斯酸催化还原得到式Ⅰ的3α‑高托品烷胺粗品，3α‑高托品烷胺粗品直接用于格拉司琼的制备或3α‑高托品烷胺粗品经纯化后用于格拉司琼的制备；二：3‑高托品酮肟经兰尼镍催化加氢还原得到高托品烷胺的混合物，纯化后得到式Ⅰ的3α‑高托品烷胺，再用于格拉司琼的制备。本发明反应条件比较温和，反应收率较高，成本较低，适合工业化生产。

  公开号：

  CN110804051B

文献信息

• Benzoxazole carboxamides for treating CINV and IBS-D
  申请人：Fairfax J. David

  公开号：US20060183769A1

  公开（公告）日：2006-08-17

  Compounds of formulae I and II: are disclosed as 5-HT 3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.

  公式I和II的化合物： 被披露为5-HT3受体拮抗剂。那些表现出中枢活性的化合物对治疗CINV有用；那些抑制外周受体的化合物对治疗IBS-D有用。
• Process for the production of aminoazobicycloalkanes from oximes
  申请人：SmithKline Beecham p.l.c.

  公开号：US05856489A1

  公开（公告）日：1999-01-05

  A process for preparing a compound of formula (I), wherein n is 2 or 3; which process comprises reducing a compound of formula (II), wherein R.sup.1 is hydrogen or C.sub.1-4 alkyl and n is 2 or 3; by catalytic hydrogenation in the presence of a rhodium catalyst. ##STR1##

  一种制备式（I）化合物的过程，其中n为2或3；该过程包括在存在铑催化剂的情况下通过催化氢化还原式（II）化合物，其中R.sup.1是氢或C.sub.1-4烷基，n为2或3。 ##STR1##
• Azabicyclo[3.3.1]nonanes
  申请人：Beecham Group p.l.c.

  公开号：US04705858A1

  公开（公告）日：1987-11-10

  Certain endo-9-lower-alkyl 9-azabicyclo[3.3.1]nonane-3-amines are valuable intermediates for the preparation of 2-methoxy-4-amino-5-halo-N-[9-lower-alkyl]-azabicyclo[3.3.1]nonanylbenzami des wherein said final products possess useful pharmacological activity, such as ability to regulate gastro-intestinal function, anti-emetic activity and CNS activity.

  某些9-内酰基-9-低烷基-3-胺基-9-氮杂双环[3.3.1]壬烷是制备2-甲氧基-4-氨基-5-卤代-N-[9-低烷基]-氮杂双环[3.3.1]壬基苯甲酰胺的有价值中间体，其中所述最终产物具有有用的药理活性，例如调节胃肠功能、抗恶心活性和中枢神经系统活性。
• Pharmaceutically active aza-bicyclo-benzamide derivatives
  申请人：Beecham Group, Limited

  公开号：US04273778A1

  公开（公告）日：1981-06-16

  This invention relates to novel substituted benzamides having useful pharmacological properties, to pharmaceutical compositions containing them, and to a process for their preparation. N-(2-Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide, 1-ethyl-2(2-methoxy-5-sulphamoylbenzamidomethyl)pyrrolidine and N-[4'-(1"-benzyl)-piperidyl]-2-methoxy-4-amino-5-chlorobenzamide are well known compounds having useful pharmacological activity such as the ability to regulate the gastro-intestinal function anti-emetic activity and CNS activity. It has now been found that a certain structurally distinct class of substituted benzamides also has useful pharmacological activity, in particular dopamine antagonist activity.

  本发明涉及具有有用的药理特性的新型取代苯甲酰胺、含有它们的制药组合物以及它们的制备方法。N-(2-二乙氨基乙基)-2-甲氧基-4-氨基-5-氯苯甲酰胺、1-乙基-2(2-甲氧基-5-磺酰胺基苯甲酰胺甲基)吡咯烷和N-[4'-(1"-苄基)-哌啶基]-2-甲氧基-4-氨基-5-氯苯甲酰胺是已知的具有有用药理活性的化合物，如调节胃肠功能、抗恶心活性和中枢神经系统活性。现在发现一类结构上独特的取代苯甲酰胺也具有有用的药理活性，特别是多巴胺拮抗活性。
• Pharmaceutically active tropanes
  申请人：Beecham Group p.l.c.

  公开号：US04544660A1

  公开（公告）日：1985-10-01

  A compound of the formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group; R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, C.sub.2-7 acyl, C.sub.2-7 acylamino, or amino, aminocarbonyl or aminosulphone optionally substituted by one or two C.sub.1-6 alkyl groups, C.sub.1-6 alkylsulphone or nitro; R.sub.5 is hyrogen or C.sub.1-6 alkyl; R.sub.6 is C.sub.1-7 alkyl or a group --(CH.sub.2).sub.s R.sub.7 where s is 0 to 2 and R.sub.7 is a C.sub.3-8 cycloalkyl group, or a group --(CH.sub.2).sub.t R.sub.8 where t is 1 or 2 and R.sub.8 is C.sub.2-5 alkenyl or a phenyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and halogen; and n, p and q are independently 0 to 2; have useful pharmacological activity.

  化合物的化学式（I）及其药学上可接受的盐：##STR1## 其中：R.sub.1是C.sub.1-6烷氧基团；R.sub.2和R.sub.3相同或不同，可以是氢、卤素、CF.sub.3、C.sub.2-7酰基、C.sub.2-7酰胺基、氨基、氨基甲酰基或氨基磺酰基，可选地被一个或两个C.sub.1-6烷基、C.sub.1-6烷基磺酰基或硝基取代；R.sub.5是氢或C.sub.1-6烷基；R.sub.6是C.sub.1-7烷基或一个基团--(CH.sub.2).sub.sR.sub.7，其中s为0至2，R.sub.7是C.sub.3-8环烷基，或一个基团--(CH.sub.2).sub.tR.sub.8，其中t为1或2，R.sub.8是C.sub.2-5烯基或一个苯基，可选地被一个或两个C.sub.1-6烷基、C.sub.1-4烷氧基、三氟甲基和卤素中的一种或两种取代；n、p和q独立地为0至2；具有有用的药理活性。